{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 76,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Uses MIDD (Model-informed drug development) as a core methodology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/45",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Applying biological/statistical models from clinical and preclinical data to: Assess benefits/risks and inform decisions; Better define therapeutic index (TI) and maximise patient benefit; Healthy volunteer study to facilitate optimisation of TI",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c9cdc20-85b3-4be0-846a-a5ff8b20fff8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.5,
        "x": 0.45,
        "y": 0.15
      },
      "kind": "list",
      "text": "IND submission in 1Q 2024; Expect to commence healthy volunteer study in US: Establish therapeutic dose, Enable combination therapy studies at outset; Following completion of healthy volunteer study: Commence simultaneous trials in AML and SCLC; Patient selection work ongoing with precision medicine platform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80a57a23-7ed8-46e2-86a3-b3980dff9b27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "paragraph",
      "text": "Model-informed drug development (MIDD)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b4b2a5a-5a92-4189-8699-c681fd4867c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "539 Moving into the clinic",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d912f3b-9da0-4664-8d27-3b685c53d56e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Model-informed drug development (MIDD)",
      "slug": null,
      "matchId": "89e802c2-794f-4b5c-ac59-5bc13d6a38f8",
      "evidence": "Explicitly stated as the methodology for clinical development",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}